Last reviewed · How we verify
BAY86-4891
At a glance
| Generic name | BAY86-4891 |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia
- Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension (PHASE2)
- Low-dose Hormone Therapy for Relief of Vasomotor Symptoms (PHASE3)
- Endometrial Safety Study (PHASE3)
- Treatment of Vasomotor Symptoms in Korean Post Menopausal Women (PHASE3)
- Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women (PHASE3)
- A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles (PHASE2)
- Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAY86-4891 CI brief — competitive landscape report
- BAY86-4891 updates RSS · CI watch RSS
- Bayer portfolio CI